PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Ligand Pharmaceuticals Incorporated

USPTO PatentsView assignee record - 37 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ligand ranks #8,635 of 50,000 tracked US assignees by granted-patent volume, with 37 patents across 11 technology areas.

#8,635
of 50,000 US assignees by volume
Top 40%
by Innovation Score (38.8/100)
15.5
avg claims per patent
-38%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8635 · US Corporation #8,635 · 37 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-SMALL 37 grants
  • UPPER-Q #8,635/50,000
  • PHOTO-FINISH Lamplight Farms Inco…
  • CPC-FOCUS A61P · 11 areas
  • INNOV-THIN 38.8/100
  • CLAIMS-RICH 15.5 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -38% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Lamplight Farms Incorporated (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Ligand

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Ligand Pharmaceuticals Incorporated stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-FOCUS, INNOV-THIN, CLAIMS-RICH, TYPE-USCORP, VEL-DOWN, BOOK-FULL. Volume places it #8,635 of 50,000; Innovation Score 38.8/100 sits in the top 40% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Lamplight Farms Incorporated (±0 grants).

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Portfolio overview

Ligand Pharmaceuticals Incorporated has been granted 37 US utility patents between 2015 and 2025, placing Ligand Pharmaceuticals Incorporated at #8,635 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.5 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Ligand Pharmaceuticals Incorporated is one of the more focused assignees in the PatentsView dataset. By volume, Ligand sits between Lamplight Farms Incorporated (37 patents, rank #8,630) and Mitsui Chemicals AGRO, Inc. (37 patents, rank #8,638) - the closest US assignees by grant volume. The composite Innovation Score of 38.8/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 13 grants, compared with 21 in the 2015–2019 window, a -38% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Ligand Pharmaceuticals Incorporated's 15.5 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 11 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Ligand's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Ligand holds 37 patents at rank #8,634, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Ligand

By rank, the assignees closest to #8,634 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Ligand's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Ligand, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Venatorx Pharmaceuticals, Inc. 39 Advanced Architectural Products, Llc 39 Leo Pharma A/s 39 Guangdong Jiamei Ceramics Co., Ltd. 39

Ligand's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0246810 20152016201720182019202020212022202320242025 3
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Ligand Pharmaceuticals Incorporated patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 2 5.4%
2016 4 10.8%
2017 4 10.8%
2018 8 21.6%
2019 3 8.1%
2020 5 13.5%
2021 1 2.7%
2022 3 8.1%
2023 2 5.4%
2024 2 5.4%
2025partial year 3 8.1%

Which technologies does Ligand Pharmaceuticals Incorporated patent most?

Top 11 of 11 technology areas

Where it ranks

Overall rank by patents

#8,635

of 50,000 tracked assignees

Innovation Score

38.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.